ReviewMini reviews in medicinal chemistry2026
Chalcones as Multi-target Ligands for Alzheimer's Disease: A Review of Synthetic Strategies and Therapeutic Promise.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imidazo[1,2‑ACS omega · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlzheimer's disease remains a multifactorial neurodegenerative disorder with limited therapeutic options. Chalcones, flavonoid-derived molecules with high structural flexibility and diverse biological activities, have emerged as promising candidates due to their ability to inhibit Aβ aggregation and cholinesterase activity. Recent research highlights their relevance as multi-target agents suitable for early-stage drug discovery.
methodsThis review compiled and analyzed studies published between 2022 and 2025 on chalcones and their derivatives with anti-Alzheimer's potential. Data were extracted regarding biosynthetic origins, synthetic strategies, physicochemical properties, and biological activities, including inhibitory potencies against AChE, MAO-B, and Aβ aggregation.
resultsNumerous chalcone-based compounds exhibited significant activity against key Alzheimer's disease targets, such as A DISCUSSION: Chalcones represent a privileged scaffold suitable for medicinal chemistry optimization, offering ease of synthesis and adaptable chemical space for structure-activity relationship exploration. Their multi-target nature aligns with the complexity of Alzheimer's disease. However, challenges remain, including selectivity, pharmacokinetics, and translation from preclinical models to therapeutic relevance.
conclusionChalcones and their derivatives show strong preclinical promise as multi-target agents for Alzheimer's disease. Continued structural optimization and biological evaluation may advance these compounds toward disease-modifying therapies, supporting their potential role in future drug discovery efforts.
Indexed as
Identifiers
41742613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.